Disruption of RANTES/CCL5-CCR5 axis with the anti-CCR5 antibody leronlimab reduced IL-6 plasma leves and plasma viral load in COVID-19 patients (Patterson et al., 2020). This evidence concerns the gene CCL5 and COVID-19.